ARCC-4

 CAS No.: 1973403-00-7  Cat No.: BP-400075  Purity: 99% 4.5  

ARCC-4 is an androgen receptor PROTAC based on an enzalutamide-derived AR ligand and a von Hippel-Lindau-recruiting ligand. The AR-binding portion recognizes the receptor ligand-binding domain, while the VHL ligand recruits the VHL ubiquitin-ligase complex through the opposite end of the molecule. This design allows ARCC-4 to act as a degrader rather than merely a receptor antagonist, because linker-mediated ternary-complex formation brings AR into a ubiquitination-competent environment. Mechanistically, ARCC-4 promotes AR ubiquitination and proteasomal depletion, including degradation of receptor variants or mutants relevant to antiandrogen research models as described in public summaries. It is useful for investigating AR protein dependence, resistance-associated receptor biology, nuclear receptor degrader selectivity, VHL-based PROTAC design, and comparative studies of transcriptional outcomes after receptor blockade versus receptor removal.

ARCC-4

Structure of 1973403-00-7

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
PROTAC
Molecular Formula
C53H56F3N7O7S2
Molecular Weight
1024.18

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • Comprehensive PROTAC Platform
  • Scientific Expertise & Technical Support
  • Custom Synthesis & Design Service
  • Extensive Product Coverage
  • Cutting-Edge Innovation
  • Fast Delivery & Global Support
  • 24/7 customer service
  • 100% quality assurance
Popular Publications Citing BOC Sciences Products
Purity
99%
Solubility
In DMSO: 200 mg/mL (195.28 mM; Need ultrasonic)
Storage
Powder, -20°C, 3 years; 4°C, 2 years; In solvent, -80°C, 6 months; -20°C, 1 month
Shipping
Room temperature in continental US; may vary elsewhere.
IUPACName
(2S,4R)-1-[(2S)-2-[[2-[4-[4-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]phenyl]phenoxy]butoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide
Synonyms
ARCC-4; 1973403-00-7; (2S,4R)-1-((S)-2-(2-(4-((4'-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-[1,1'-biphenyl]-4-yl)oxy)butoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide; CHEMBL4540528; SCHEMBL17946930; DUPAJELXESPTNF-PPZGWQTASA-N; AKOS040741162; MS-31874; HY-130492; CS-0108331; EN300-7526556; Z3482428589; O1-(ABM-14 ether), O4-(Methylcarboxamide with AHPC) Butanediol; (2S,4R)-1-[(2S)-2-(2-{4-[(4'-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-[1,1'-biphenyl]-4-yl)oxy]butoxy}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
InChI Key
NBHWEDHRTGEGEB-VKZLHUHRSA-N
InChI
InChI=1S/C53H56F3N7O7S2.H2O/c1-32-45(72-31-59-32)36-11-9-33(10-12-36)28-58-47(66)43-26-40(64)29-61(43)48(67)46(51(2,3)4)60-44(65)30-69-23-7-8-24-70-41-21-16-35(17-22-41)34-13-18-38(19-14-34)63-50(71)62(49(68)52(63,5)6)39-20-15-37(27-57)42(25-39)53(54,55)56;/h9-22,25,31,40,43,46,64H,7-8,23-24,26,28-30H2,1-6H3,(H,58,66)(H,60,65);1H2/t40-,43+,46-;/m1./s1
SMILES
CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)C3CC(CN3C(=O)C(C(C)(C)C)NC(=O)COCCCCOC4=CC=C(C=C4)C5=CC=C(C=C5)N6C(=S)N(C(=O)C6(C)C)C7=CC(=C(C=C7)C#N)C(F)(F)F)O.O
Mechanism

Target: ARCC-4 selectively targets androgen receptor and clinically relevant AR mutant variants.

Binding site: Its enzalutamide-derived ligand binds the androgen receptor ligand-binding domain.

Mechanism of action: ARCC-4 is a VHL-recruiting androgen receptor PROTAC based on an enzalutamide-derived AR antagonist linked to a VHL E3 ligase ligand. The compound induces proximity between AR and the VHL ubiquitin ligase complex, resulting in AR ubiquitination and proteasome-dependent degradation. This mechanism enables direct removal of AR protein, including mutant forms, rather than competitive suppression of ligand-dependent transcription alone. ARCC-4 is useful for studying AR degradation kinetics, mutant receptor susceptibility, transcriptional pathway shutdown, and experimental differences between receptor antagonism and targeted receptor depletion.

Applications

• PROTAC-Mediated Kinase Degradation: ARCC-4 is utilized in research to selectively degrade kinases, offering a novel approach to study kinase signaling pathways. This facilitates the investigation of cellular processes and the identification of potential therapeutic targets by modulating kinase activity through targeted protein degradation.

• Targeted Degradation in Cancer Research: Researchers employ ARCC-4 to explore the degradation of oncogenic proteins, providing a powerful tool to dissect cancer cell biology. By precisely removing specific proteins, scientists can better understand tumorigenesis and identify vulnerabilities within cancer cells.

• PROTAC-Based Drug Resistance Studies: ARCC-4 aids in the study of drug resistance mechanisms by degrading proteins involved in resistance pathways. This application allows researchers to pinpoint critical nodes in resistance networks and develop strategies to overcome therapeutic challenges.

• Cellular Pathway Analysis via PROTACs: ARCC-4 is instrumental in mapping cellular pathways by degrading key regulatory proteins. This targeted approach helps elucidate complex biological networks and the roles of specific proteins in maintaining cellular homeostasis.

1. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
Taavi K Neklesa, Nick J Vitale, Jemilat Salami, Jing Wang, Ryan R Willard, Meizhong Jin, Donald P McDonnell, Craig M Crews, Shanique Alabi, Andrew P Crew, Hanqing Dong Commun Biol . 2018 Aug 2;1:100. doi: 10.1038/s42003-018-0105-8.
The androgen receptor is a major driver of prostate cancer and inhibition of its transcriptional activity using competitive antagonists, such as enzalutamide remains a frontline therapy for prostate cancer management. However, the majority of patients eventually develop drug resistance. We propose that targeting the androgen receptor for degradation via Proteolysis Targeting Chimeras (PROTACs) will be a better therapeutic strategy for targeting androgen receptor signaling in prostate cancer cells. Here we perform a head-to-head comparison between a currently approved androgen receptor antagonist enzalutamide, and its PROTAC derivative, ARCC-4, across different cellular models of prostate cancer drug resistance. ARCC-4 is a low-nanomolar androgen receptor degrader able to degrade about 95% of cellular androgen receptors. ARCC-4 inhibits prostate tumor cell proliferation, degrades clinically relevant androgen receptor point mutants and unlike enzalutamide, retains antiproliferative effect in a high androgen environment. Thus, ARCC-4 exemplifies how protein degradation can address the drug resistance hurdles of enzalutamide.
ConcentrationVolumeMass1 mg5 mg10 mg
1 mM0.98 mL4.88 mL9.76 mL
5 mM0.2 mL0.98 mL1.95 mL
10 mM0.1 mL0.49 mL0.98 mL
50 mM0.02 mL0.1 mL0.2 mL

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
Germany
Inquiry Basket